Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 19/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 1.00 |
| ▸ | IL1B | P01584 | 3/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avadomide SCHEMBL634577 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442249 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29359950 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29520051 | 0.99 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29519996 | 0.99 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15515920 | 0.99 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL12099722 | 0.99 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495228 | 0.95 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495583 | 0.95 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | US | claimed |
| EP-4327878-A2 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Juno Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| EP-3618842-B1 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JUNO THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | claimed |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2023-08-22 | — | — | US | claimed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | claimed |
| EP-3641772-B1 | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION | CELGENE CORP (US) | 2023-08-02 | — | — | EP | claimed |
| EP-4171550-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | Celgene Corporation (US) | 2023-05-03 | — | — | EP | claimed |
| CN-115916191-A | Methods of treating cancer with combination therapy | 新基公司 | 2023-04-04 | — | — | CN | claimed |
| US-20220008477-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | US | claimed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | claimed |
| WO-2014004990-A2 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS | CELGENE CORPORATION (US) | 2014-01-03 | — | — | WO | claimed |
| US-20130183675-A1 | BIOMARKERS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CELGENE CORPORATION (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013106686-A1 | BIOMARKERS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CELGENE CORPORATION (US) | 2013-07-18 | — | — | WO | claimed |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2012-12-20 | — | — | US | claimed |
| WO-2012149299-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORAITON (US) | 2012-11-01 | — | — | WO | claimed |
| WO-2012125475-A1 | USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2-6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2012-09-20 | — | — | WO | claimed |
| WO-2012125459-A1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2012-09-20 | — | — | WO | claimed |
| WO-2012125438-A1 | SOLID FORMS OF 3-(5-AMINO-2METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORPORATION (US) | 2012-09-20 | — | — | WO | claimed |
| US-20120232100-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORPORATION | 2012-09-13 | — | — | US | claimed |
| US-20120230983-A1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2012-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | CRBN 1/4885DDB1 946/4885IKZF3 1416/4885 |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | CRBN 17/4885DDB1 1046/4885IKZF3 54/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | CRBN 5/4885DDB1 52/4885IKZF3 4/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | CRBN 1387/4885DDB1 485/4885IKZF3 266/4885 |
| US-20120232100-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALPP, DPYD | CRBN 785/4885DDB1 2493/4885IKZF3 3449/4885 |
| US-20220008477-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | CRBN 17/4885DDB1 1046/4885IKZF3 54/4885 |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885IKZF3 1204/4885 |
| US-20120230983-A1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | VHL, TP53, MGMT | CRBN 1487/4885DDB1 593/4885IKZF3 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.